Reddit Posts
Insiders buying up small-cap Biotech Stock ($BCAB, $SYRS, $PLSE, $ERAS, $LQDA, $CATX)
Insiders buying up every Biotech Stock ($PLSE, $ERAS, $LQDA, $CATX)
Insiders buying up every Biotech Stock ($PLSE, $ERAS, $LQDA, $CATX)
Thanks for the LQDA heads up pharma bro. Up 6k and not selling anytime soon.
Did I take financial advice from a convicted felon ? Yes. Is it working out ? Also yes. LQDA 15k yolo (ty Martin Shkreli)
LQDA regards, I know you’re out there, answer my mating call.
Thanks Shkreli! Anyone else happy about LQDA so far? 📈
Anybody else here happy about here for the LQDA…?
$LQDA Martin Shkreli posted about it about 3 weeks ago DD with Squeeze Potential
$LQDA - FDA approval and Martin Skreli
The week's top DDs and Discussions in the Reddit world [No Memes]
LQDA - Never heard of the company until today but I’m in for $40k
A year ago I had my friends randomly pick letters and put $5k in that sticker. They picked LQDA and now I'm up 136%...I owe them beers.
Biotech Penny Stocks To Watch This Month With Potential Catalysts - $TNXP $LQDA $CRVS $AGEN $PHAS
Mentions
LQDA is a biotech waiting on a court ruling. It’s likely to go in their favor and should come soon. Wont be 5x more like +30% but also expected in the next 1-2 months. Obviously this is a binary event of ruling goes against them it drops but that is unlikely but do your own due diligence.
LQDA - went from 12$ to 45$ in a span of a year. Shkreli had a post about the company on WSB 2 year ago RVMD - oncology drug maker. WSJ was reporting multiple companies including Merck are interested in a buyout. 3x in year. ABVX another biotech buyout target
That is pretty much what LQDA has done for years to compete with JnJ and UTHR. I mean what you are worrying would take another several years of R&D and trials
#TLDR --- Ticker: LQDA Direction: Up Prognosis: Buy Shares (Long hold through 2027) Catalyst: Eating JNJ and UTHR's lunch with a superior drug (Yutrepia) The Math: 6,750 patients @ $140k/yr = $900M Revenue
LQDA will be bought out at some point by Merck or j&j
Since it's not been mentioned, LQDA
The drug contributes 95% of their revenue , the remaining is generic. 60% of UTHR’s revenue is from Tyvaso(the direct competitor that LQDA is eating market share away from)
LQDA is my bet. It’s an easy doubler. They’re a commercial biotech company. Shkreli had posted about them in this subreddit a few years ago. Their stock price has quadrupled since then. Last quarter, they reported 2000 unique prescriptions for their hypertension drug. They plan to increase this to 10000 prescriptions in the next year.(the drug costs 300k annually) Currently, LQDA has a market capitalization of 3 billion dollars. In comparison, their competitor, UTHR, has a market capitalization of 22 billion dollars.
Had LQDA for a couple years and that finally got to where I hoped it would this year. Currently up about 150% on LMND now after lots of averaging up however plan to hold that for a very long time.
What are your thoughts on small cap commercial biotech? Quite a few look very attractive but the market doesn't think so. From my side, you're not relying on data catalysts as such and its really just a case of commercialisation going well. Off the top of my head things like HROW, ETON, Delcath, LQDA, ABEO, SLNO.
Thoughts on LQDA? No one else was talking about it and sentiment seems up from wall street.
I invested in CLS a couple of years ago in my small portfolio and it has blown up since then. I'm now sitting at about 55% of my portfolio in just CLS, with some of the remaining being in MMM, RKLB, LQDA and HPE all doubling their return or more. I'd like to make some moves and add some other stocks to my portfolio by selling off about half of my CLS shares and getting around $4,000 from that. What would be some good, safe stocks that I could add with that return? Or should I just get more shares of what I currently have?
I bought SNDX at 9.20 and anticipate it going to 28-30. I bought TARS at $40, hanging tight. Recently buying the heck out of VKTX and SRPT. Got 5,000 shares of SRPT below $18 and honestly think it’s going back to $80. Bought ETHA Dec calls in June. Up 540% and absolutely not selling. Bought LQDA at $19 in anticipation of earnings Monday. Rocking now. HROW been an absolute winner. I have others that I’m not selling. Building a position in IDYA. Supposed to release data today but it got embargoed. I think it’s gonna be exceptional, and is being delayed to Sept
Been loving Tim, and looks like he’s staying true to his word that he is no longer posting on Twitter since LQDA hit $25 today. I’ve gotten some great insight from following him, let me know if you find him anywhere else or others like him.
$LQDA +16% premarket YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD
$LQDA to the mf moon let’s gooooooooooo
Puts on LQDA, not sure how much more it'll run up after earnings.
I got $200k in SNDX. Bought low 9s. They are executing very well. One of their drugs is collab with INCY, and they just had a board member (Bill Meury) resign in June and joined as INCY new CEO. I think INCY may buy them out. Looking at $24-30 range. Meury has a history of acquisitions so this is my bet. Heavy options activity on LQDA. They got through some litigation and are finally able to sell their drug. Inhaled drugs are super hot now (look up VRNA ). Earnings coming out 12th. I’m not the biggest ER player but if they have good sales, it’s gonna explode higher. CRNX is a quiet play, waiting for drug approval in Sept. they have an oral drug for Acromegaly. “Should” be approved because study was double blind. After that they’ll ramp up sales and should do well. With biotech usually you wanna see if the first quarter after launch is good and see traction. Massive risk-reward plays: SRPT and VKNG. Both have +400% potential
I can’t answer your question what/if to sell and what to buy, but LQDA and ASTS both look speculative, pre profit, will be roller coaster rides and they are about 30-percent of this account, which is high for speculative holdings, so yeah, as you noted, the acct is down at the moment.
I think it looks good apart from ASTS and LQDA. You are strongly weighted towards the NASDAQ, which is currently highly overvalued. I would suggest broadening holdings to some ex-US for a bit of balance. About 5% in a gold ETF will protect you in a bear market. About 5-10% in bitcoin will give you growth but not too much volatility.
Thanks for the advice, I do need some international equity, LQDA looking like a sell right now.
You're off to a decent start with VOO and some GOOG/NVDA, but ASTS and LQDA are speculative and not exactly core holdings. You're young, so dabbling is fine, but don’t mistake gambling for strategy. Your Roth is way cleaner than your brokerage. Check this breakdown of your Roth allocation: https://www.insightfol.io/en/portfolios/report/e82c05b045/
LQDA at shkrelis price target…. THANK YOU SHKRELI!!
I was long LQDA. Was in my short basket.
because that was when the total market for this was projected to be 900 million and now it is 1.8 billion and also that was when it was projected lqda gonna take 20-27% of market but right now they are taking 50% of new patients shkreli put in a lot of conservative estimates and LQDA is well exceeding them
LQDA up 25% in \~4 days and continuing to climb. No memes :)
LQDA a bit of a brightspot today
LQDA you fkn beauty. Give me 15 next week. Keep it up!
Double down on LQDA. Don't sleep on it. It's breaking out. Straight to 15 next. I can see it 20+ after earnings in a month.
LQDA held support at April lows. It looks like it's about to reverse. Earnings in 30 days. Target price $15.
In case of LQDA it is not a might, but a will. They will take away. And if you‘d done your research you‘d know that most of UTHRs valuation is based upon Tyvaso which is exactly where LQDA is aiming at with Yutrepia. Being the big player wont do it, especially when the mew available alternative is better which was proven in studies. Liquidia even studied how patients can switch product. This is serious danger my guy.
Yeah i agree that LQDA and INSM might chip away at UTHR’s business a bit, but UTHR is still the big player with a really strong position. They’ve got solid products, great relationships with insurance companies, and plenty of cash. So, while the competition is heating up, UTHR isn’t about to lose its top spot anytime soon.
Insmed also had solid news on their drug, which is why both LQDA and UTHR are having bad days. Sounds like there might be a third player in the space soon.
Are you numb? LQDA literally got approval of their dry powder treatment for PAH and PH-ILD and according to studies it is better than UTHRs product. Their revenue is in danger and so is their margin.
UTHR and LQDA are getting crushed today.
LQDA will be mooning shortly... the ascent has begun
LQDA up 11% pre market
Calls on LQDA before it’s too late
Loaded up on LQDA and SOXL calls this week 🚀
I’m still holding despite the decrease in price. I was expecting price to drop leading up to the announcement because people want to profit on the hype. But I still think the FDA will approve, which will hopefully send LQDA much higher in price
I am holding over 18,000 shares, I am hoping the court case today in North Carolina does not cause some last minute issues. I have been in and out of LQDA for two years and learned more about our court systems then I would care to. Let’s hope we get paid week.
What do you think about LQDA? FDA PDUFA date also coming soon (24th May).
Oh god I am just still waiting, same game plan as before. But this market we have been in this year has been tough. If the market can hold up then so can this but if the market pulls back more then LQDA will have a tough time.
They got screwed when the FDA recently ruled against themselves when they granted another year of exclusivity to United for there patent on Tyvaso. LQDA has an inhalation powder called Yutrepia which is superior to Tyvaso, which is the drug that generates the most revenue by far for United Theraputics. There is clearly collusion and corruption going on between the FDA and United. The United CEO has done this to other companies in the past, trying to tie them up in litigation and court cases and bleed them white so if and when they win in court they won't be able operate and launch to market because of all the resources burned in court. But! LQDA secured funding and they're suing both FDA and United. I feel I'm on the right side morally and from an investing standpoint. I have a buy in at $8.62.
can you share insight on your position and expectation on LQDA
|| || |Top 10 Stock Positions|Weight| |LQDA|11.74%| |MDT|9.28%| |PM|9.46%| |SYK|7.36%| |NMIH|5.46%| |VNOM|4.23%| |CCEC|4.81%| |X|4.47%| |Ebay|4.43%| |FRMO|4%|
LQDA to $11.25 28 may of next year.
I’ll trade you my LQDA calls for your shit ones
I bought LQDA last week and bought some more today. Hope it doesn’t tank.
Where’s the guy who had LQDA calls 
Been watching LQDA for awhile and instantly jumped in once it crashed up about 10% now :)
It's cool that ASTS is mooning, I just wish IBRX did something other than lose value. Also LQDA crashing this morning was fun.
I bought a bunch of LQDA because of some regarded post on here.
I sold all my Costco shares to go ham on LQDA from this post and I don’t regret it…yet.
Its a commercial stage biotech that hasn't run yet, the CFO sold his last 3 companies at multiples. Of course the timeline is speculative, by all accounts its a value play. LQDA should get full FDA approval early next week, although there is a tiny chance of the opposite, stock would probably go to 8 bucks in that scenario. If approval is given it should go high teens in short order, and am personally looking for 25-35 over the next 6-18 months. I have a large position from sub 7 though (when it was more risky ofc). At the other end theres SPRB, 18m mkt cap 70m in cash. Its a shitco but good chance it goes 1-2 bucks+ on something stupid as it is so beaten up bearing in mind cash. YMMV applies.
LQDA will likely get FDA approval today or Monday. It's been a LONG time coming. 25% short interest. Currently 14.25. 25+ price targets. Good luck
LQDA will likely get fda approval Friday. Yesterday a sealed document was filed by the FDA in the lawsuit between UTHR, the FDA, and LQDA. The FDA is required by the court to give three day notice of an approval decision. Three days from yesterday is Friday. Do with that what you will. I have September calls and $100k in shares
I hold LQDA and I have same question as OP's question number 2. How much bump can I expect with looming interest cuts. Is it justifiable to keep money in lqda instead of a equity index fund for next 2 years (assuming interest rates are cut by fed over next 2 years)
A number of traditional unrelated plays suddenly have an AI correlation, like utilities and energy (supplying power to datacenters), commodities (uranium for energy, copper for datacenters), and even Berkshire (Apple stake). I’d suggest farther afield, less market correlated plays like;m LQDA (drug for pulmonary arterial hypertension), UAN (fertilizer plant selling at a discount), and BOOM (small cap with three divisions that just received a buyout offer). I’m also liking UnitedHealth but it’s correlated to the market I’m guessing.
I don't have a position in Skywest. Management has been aggressively doing buybacks from what I've heard which is why it has gone up. I only have a small position in LQDA. It is waiting for FDA approval
Risers: Skywest Airlines (SKYW) having a strong morning Liquidia (LQDA): +17% https://www.globenewswire.com/news-release/2024/06/03/2892111/0/en/District-Court-Issues-Favorable-Ruling-and-Denies-United-Therapeutics-Request-to-Block-YUTREPIA-Launch.html Pullback for Powell Industries, it badly needed one.
LQDA is the answer! Expecting high teens after FDA approval.
Fuck it, I don’t have a good move in mind so I’ll probably just dump more money in LQDA.
LQDA, IBRX, and I pick up GME and sell covered calls on it when the price gets low enough.
100%. If I wanna puke while looking at my 401k or IRA, that means it's time to buy in my individual. I check around 3:15 every day. Bought a bunch of QQQM, AMZN, and LQDA at close on Friday as well.
Will LQDA get FDA approval next week? I have 17.5c expiring 4/19, trying to decide if i should hold or dump. If approval happens I wouldn't be surprised if they 10x.
Hope that LQDA gets FDA approval on Monday.
You have 5 minutes to get into LQDA before a likely FDA approval April 1st.
No, it happened a few days ago too. I bet this one hits too: !banbet LQDA 20 2w
LQDA isn't 20... What's going on here?
$LQDA gonna go nuts after April. Mark my words.
$LQDA earnings tomorrow morning pray for me
Game calls LQDA calls MARA calls 
Look into LQDA, they are taking over a patent from a other company. Estimated to generate about 500 million in revenue (currently does for them) but since liquidia will be taking a part of that markets revenue You can bet it’ll be worth more than 1 billion dollars
1. SMCI 2. CELH or FOUR 3. LQDA 15c for April
LQDA. Not the average biotech gamble 🫶
**Liquidia** * treprostinil-inhaler for PAH patients on it's way. UTHC currently has the whole market. $7b worth from Tyvaso & Tyvaso DPI alone; $3b from other PAH stuff. * From UTHC's valuation LQDA's worth (if successful obv.) can be estimated: 50:50 marketshare for both could mean $3,5b for LQDA, currently at under $1,0b. Other pipeline therapies for PAH could give them another fair share of UTHC's valuation. * patent lawsuit from UTHC is bs, they even tried to buy LQDA before that. Why would you try to buy a competitor if their product is breaking your patents? Because they are not. * LQDA CEO previously was high up in the ranks of UTHC. Should know PAH business. * FDA approval seems quite plausible (still a gamble!), as the generic drug treprostinil is well known, it's just the patent and technology for it to become a powder-inhaler is new (and as such still possible of being disapproved by FDA). UTHC already has such inhaler (both as powder and solution) approved. * Insider buy-ins Nov. & Dec (many executives). Blackrock joined with roughly 5% earlier in Feb. -> bullish AF Cirata, Eventbrite: no comment tho